|

S241656 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: BDTX-4933

Pipeline

Phase 1/2: 1

Top Sponsors

  • Institut de Recherches Internationales Servier1

Indications

  • KRAS G13D1
  • KRAS G12R1
  • KRAS G12F1
  • KRAS G12A1
  • Acquired Resistance to KRAS G12C Inhibitor1

Gilbert, Arizona1 trial

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.